Revolutionizing remote chronic disease management with AI-driven Bloodless Blood Tests
What is the Challenge?
Heart failure is a chronic and progressive condition that affects over 26 million individuals globally. These patients constitute 30% of global hospital readmissions, totaling $6.6B in costs in 2019, and tripling by 2025. Less than 1% of Heart Failure patients are on optimal guideline directed medical therapy (GDMT) due to poor remote monitoring options, causing patients that could otherwise be stabilized to end up readmitted.
Current Heart Failure remote patient monitoring options are ineffective due to inaccuracy, user burden, and cost. Clinical studies have shown that maintaining optimal GDMT reduces hospital readmissions and improves long-term mortality. The key to increasing the number of patients on optimal GDMT is to inform cardiologists via effective remote monitoring about patients who are not responsive to their current therapy, such that it may be updated and optimized.Could remote monitoring be the key to keeping cardiologists informed about their patients' therapy responses more effectively?
What is the Solution?
General Prognostics (GPx) is revolutionizing remote chronic disease management with the world's first AI-driven Bloodless Blood Tests. GPx is a clinical-stage company dedicated to transforming the standard of heart failure remote monitoring and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.
GPx’s Bloodless Blood Test platform delivers continuous blood biomarker monitoring to identify significant patient status changes on a timely and cost-effective basis through sophisticated algorithms that correlate passively-collected non-invasive biomarkers with vital HF blood-biomarkers such as NT-proBNP. Through Bloodless Blood Tests, physicians gain the benefit of serial blood testing, without the high cost and burden for the patient. This platform works within current HF guidelines for monitoring patient status via NT-proBNP, a Class I recommendation for ongoing monitoring, therefore translating the patient’s status into the language used by physicians. GPx completed its 230-patient phase 2 clinical study and achieved a promising algorithm per